Predictive Value of CEA and ctDNA in Lung Cancer Recurrence
ConditionLung Carcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age15-100
SponsorGuangdong Provincial People's Hospital
About this trial
The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.
Eligibility criteria
Qualifiers
Preoperative CEA > 5mg/l
MRD testing was conducted before the operation
The primary lesion was resected through surgery
There should be at least two CEA and MRD follow-up tests within 2 years after the operation
Disqualifiers
Those without available imaging records
Patients with a history of malignant tumors within the past five years
Patients with secondary lung cancer
Trial design
Treatments tested in this trial
- Not listed
Trial groups
100 Participants
are grouped into 2 trial groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov